NAMD Submits Comments on Medicaid Drug Rebate Program Proposed Rule
On July 25, NAMD submitted comments on CMS's proposed rule on the Medicaid Drug Rebate Program (MDRP).
Benefits
Prescription Drugs
Access to affordable prescription drugs is essential to quality care. Their impact on state budgets is also a consideration for all programs.
Resources
Prescription Drug Spending: What’s Coming Next for Medicaid and How Can States Prepare?
Experts at the NAMD Fall Conference discussed challenges with high-cost drugs.
NAMD Comments on Medicare’s Proposed Coverage Determination for Alzheimer’s Drug
On February 9, 2022, NAMD submitted comments on Medicare’s proposed National Coverage Determination (NCD) of Coverage with Evidence...
NAMD Urges CMS to Mitigate State Costs on Controversial Alzheimer’s Drug
In formal comments, NAMD calls on Medicare to step up and cover the Alzheimer’s drug Aduhelm. Failure to...
NAMD Urges Medicare to Not to Shift Cost of Alzheimer’s Drug to Medicaid
On August 11, 2021, NAMD sent a letter to CMS asking that Medicare not shift the cost of...
Medicare Must Not Cost Shift Alzheimer’s Care to Medicaid
NAMD explains the serious cost implications of Medicare’s coverage decision on the Alzheimer’s drug Aduhelm for state Medicaid...
NAMD Releases Regulatory Priorities for Biden Administration
On July 19, 2021, NAMD sent a letter to the Centers for Medicare & Medicaid Services (CMS) Administrator...
NAMD Submits Letter of Support for MACPAC’s Accelerated Approval Pathway Drug Rebate Proposal
On April 7, NAMD sent a letter to the Medicaid and CHIP Payment and Access Commission (MACPAC) supporting...